Home » Topics » BioWorld Science

BioWorld Science
RSS

Boehringer Ingelheim discloses FFAR1 agonists

May 17, 2018

Bayer patents new vasopressin V1A and V2 receptor antagonists

May 17, 2018

Novo Nordisk expands chronic disease focus beyond type 1 diabetes

May 17, 2018

Eleven Biotherapeutics changes name to Sesen Bio

May 17, 2018

European Commission approves Cabometyx for first-line treatment of advanced RCC

May 17, 2018

IDMC recommends continuation of enrollment in phase IIa study of milciclib in HCC

May 17, 2018

Eiger Biopharmaceuticals obtains rights to lonafarnib for Hutchinson-Gilford progeria syndrome

May 17, 2018

KalVista Pharmaceuticals develops new agents for diabetic retinopathy

May 17, 2018

First phase III clinical results presented for esketamine in treatment-resistant depression

May 17, 2018

FluGen's M2SR influenza vaccine begins challenge study

May 17, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...